Is Zymeworks Inc. Common Stock (ZYME) overvalued? · rev $76.3M
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
This page asks whether Zymeworks Inc. Common Stock (ZYME) looks expensive on cached numbers — not a short thesis.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
ZYME currently screens at market cap $1.68B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZYME 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZYME stock page for the full model, not this heading.
Not investment advice.